Risk Factors for Cervical Cancer
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Ovarian Cancer and Cervical Cancer
What Every Woman Should Know About Gynecologic Cancer R. Kevin Reynolds, MD The George W. Morley Professor & Chief, Division of Gyn Oncology University of Michigan Ann Arbor, MI What is gynecologic cancer? Cancer is a disease where cells grow and spread without control. Gynecologic cancers begin in the female reproductive organs. The most common gynecologic cancers are endometrial cancer, ovarian cancer and cervical cancer. Less common gynecologic cancers involve vulva, Fallopian tube, uterine wall (sarcoma), vagina, and placenta (pregnancy tissue: molar pregnancy). Ovary Uterus Endometrium Cervix Vagina Vulva What causes endometrial cancer? Endometrial cancer is the most common gynecologic cancer: one out of every 40 women will develop endometrial cancer. It is caused by too much estrogen, a hormone normally present in women. The most common cause of the excess estrogen is being overweight: fat cells actually produce estrogen. Another cause of excess estrogen is medication such as tamoxifen (often prescribed for breast cancer treatment) or some forms of prescribed estrogen hormone therapy (unopposed estrogen). How is endometrial cancer detected? Almost all endometrial cancer is detected when a woman notices vaginal bleeding after her menopause or irregular bleeding before her menopause. If bleeding occurs, a woman should contact her doctor so that appropriate testing can be performed. This usually includes an endometrial biopsy, a brief, slightly crampy test, performed in the office. Fortunately, most endometrial cancers are detected before spread to other parts of the body occurs Is endometrial cancer treatable? Yes! Most women with endometrial cancer will undergo surgery including hysterectomy (removal of the uterus) in addition to removal of ovaries and lymph nodes. -
FGM in Canada
Compiled by Patricia Huston MD, MPH Scientific Communications International, Inc for the Federal Interdepartmental Working Group on FGM. Copies of this report are available from: Women's Health Bureau Health Canada [email protected] The Canadian Women's Health Network 203-419 Graham Avenue Winnipeg, Manitoba R3C 0M3 fax: (204)989-2355 The opinions expressed in this report are not necessarily those of the Government of Canada or any of the other organizations represented. Dedication This report is dedicated to all the women in the world who have undergone FGM and to all the people who are helping them live with and reverse this procedure. This report is part of the ongoing commitment of Canadians and the Government of Canada to stop this practice in Canada and to improve the health and well-being of affected women and their communities. Executive Summary Female genital mutilation (FGM), or the ritual excision of part or all of the external female genitalia, is an ancient cultural practice that occurs around the world today, especially in Africa. With recent immigration to Canada of peoples from Somalia, Ethiopia and Eritrea, Sudan and Nigeria, women who have undergone this practice are now increasingly living in Canada. It is firmly believed by the people who practise it, that FGM improves feminine hygiene, that it will help eliminate disease and it is thought to be the only way to preserve family honour, a girl's virginity and her marriageability. FGM has a number of important adverse health effects including risks of infection and excessive bleeding (often performed when a girl is pre-pubertal). -
Primary Immature Teratoma of the Thigh Fig
CORRESPONDENCE 755 8. Gray W, Kocjan G. Diagnostic Cytopathology. 2nd ed. London: Delete all that do not apply: Elsevier Health Sciences, 2003; 677. 9. Richards A, Dalrymple C. Abnormal cervicovaginal cytology, unsatis- Cervix, colposcopic biopsy/LLETZ/cone biopsy: factory colposcopy and the use of vaginal estrogen cream: an obser- vational study of clinical outcomes for women in low estrogen states. Diagnosis: NIL (No intraepithelial lesion WHO 2014) J Obstet Gynaecol Res 2015; 41: 440e4. LSIL (CIN 1 with HPV effect WHO 2014) 10. Darragh TM, Colgan TJ, Cox T, et al. The lower anogenital squamous HSIL (CIN2/3 WHO 2014) terminology standardization project for HPV-associated lesions: back- Squamous cell carcinoma ground and consensus recommendation from the College of American Immature squamous metaplasia Pathologists and the American Society for Colposcopy and Cervical Adenocarcinoma in situ (AIS, HGGA) e Adenocarcinoma Pathology. Arch Pathol Lab Med 2012; 136: 1267 97. Atrophic change 11. McCluggage WG. Endocervical glandular lesions: controversial aspects e Extending into crypts: Not / Idenfied and ancillary techniques. J Clin Pathol 2013; 56: 164 73. Epithelial stripping: Not / Present 12. World Health Organization (WHO). Comprehensive Cervical Cancer Invasive disease: Not / Idenfied / Micro-invasive Control: A Guide to Essential Practice. 2nd ed. Geneva: WHO, 2014. Depth of invasion: mm Transformaon zone: Not / Represented Margins: DOI: https://doi.org/10.1016/j.pathol.2019.07.014 Ectocervical: Not / Clear Endocervical: Not / Clear Circumferenal: Not / Clear p16 status: Negave / Posive Primary immature teratoma of the thigh Fig. 3 A proposed synoptic reporting format for pathologists reporting colposcopic biopsies and cone biopsies or LLETZ. Sir, Teratomas are germ cell tumours composed of a variety of HSIL, AIS, micro-invasive or more advanced invasive dis- somatic tissues derived from more than one germ layer 12 ease. -
Squamous Cell Carcinoma Arising in an Ovarian Mature Cystic Teratoma
Case Report Obstet Gynecol Sci 2013;56(2):121-125 http://dx.doi.org/10.5468/OGS.2013.56.2.121 pISSN 2287-8572 · eISSN 2287-8580 Squamous cell carcinoma arising in an ovarian mature cystic teratoma complicating pregnancy Nae-Ri Yun1, Jung-Woo Park1, Min-Kyung Hyun1, Jee-Hyun Park1, Suk-Jin Choi2, Eunseop Song1 Departments of 1Obstetrics and Gynecology and 2Pathology, Inha University College of Medicine, Incheon, Korea Mature cystic teratomas of the ovary (MCT) are usually observed in women of reproductive age with the most dreadful complication being malignant transformation which occurs in approximately 1% to 3% of MCTs. In this case report, we present a patient with squamous cell carcinoma which developed from a MCT during pregnancy. The patient was treated conservatively without adjuvant chemotherapy and was followed without evidence of disease for more than 60 months using conventional tools as well as positron emission tomography-computed tomography following the initial surgery. We report this case along with the review of literature. Keywords: Dermoid cyst; Malignant transformation; Observation; Positron emission tomography-computed tomography Introduction An 18 cm solid and cystic left ovarian mass with a smooth surface and two small right ovarian cysts were detected re- The incidence of adnexal masses during pregnancy is 1% to sulting in a laparotomy at 13 weeks of gestation and left sal- 9% [1]. Mature cystic teratomas (MCT) are common during pingo-oophorectomy and right ovarian cystectomy (Fig. 1C). pregnancy with the most dreadful complication being ma- The report of the frozen section from both tissues revealed lignant transformation which occurs in approximately 1% to MCT. -
Pembrolizumab in Vaginal and Vulvar Squamous Cell Carcinoma: a Case Series from a Phase II Basket Trial Jefrey A
www.nature.com/scientificreports OPEN Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial Jefrey A. How 1, Amir A. Jazaeri 1, Pamela T. Soliman1, Nicole D. Fleming1, Jing Gong2, Sarina A. Piha‑Paul2, Filip Janku 2, Bettzy Stephen 2 & Aung Naing 2* Vaginal and vulvar squamous cell carcinoma (SCC) are rare tumors that can be challenging to treat in the recurrent or metastatic setting. We present a case series of patients with vaginal or vulvar SCC who were treated with single‑agent pembrolizumab as part of a phase II basket clinical trial to evaluate efcacy and safety. Two cases of recurrent and metastatic vaginal SCC, with multiple prior lines of systemic chemotherapy and radiation, received pembrolizumab. One patient had signifcant reduction (81%) in target tumor lesions prior to treatment discontinuation at cycle 10 following confrmed progression of disease with new metastatic lesions (stable disease by irRECIST criteria). In contrast, the other patient with vaginal SCC discontinued treatment after cycle 3 due to disease progression. Both patients had PD‑L1 positive vaginal tumors and tolerated treatment well. One case of recurrent vulvar SCC with multiple surgical resections and prior progression on systemic carboplatin had a 30% reduction in her target tumor lesions following pembrolizumab treatment with a PD‑L1 positive tumor. Treatment was discontinued for grade 3 mucositis after cycle 5. Pembrolizumab may provide some clinical beneft to some patients with vaginal or vulvar SCC and is overall safe to utilize in this population. Future studies are needed to evaluate the efcacy of pembrolizumab in these rare tumor types and to identify predictive biomarkers of response. -
Gynecological Malignancies in Aminu Kano Teaching Hospital Kano: a 3 Year Review
Original Article Gynecological malignancies in Aminu Kano Teaching Hospital Kano: A 3 year review IA Yakasai, EA Ugwa, J Otubu Department of Obstetrics and Gynecology, Aminu Kano Teaching Hospital, Kano and Center for Reproductive Health Research, Abuja, Nigeria Abstract Objective: To study the pattern of gynecological malignancies in Aminu Kano Teaching Hospital. Materials and Methods: This was a retrospective observational study carried out in the Gynecology Department of Aminu Kano Teaching Hospital (AKTH), Kano, Nigeria between October 2008 and September 2011. Case notes of all patients seen with gynecological cancers were studied to determine the pattern, age and parity distribution. Results: A total of 2339 women were seen during the study period, while 249 were found to have gynecological malignancy. Therefore the proportion of gynecological malignancies was 10.7%. Out of the 249 patients with gynecological malignancies, most (48.6%) had cervical cancer, followed by ovarian cancer (30.5%), endometrial cancer (11.25%) and the least was choriocarcinoma (9.24%). The mean age for cervical carcinoma patients (46.25 ± 4.99 years) was higher than that of choriocarcinoma (29 ± 14.5 years) but lower than ovarian (57 ± 4.5years) and endometrial (62.4 ± 8.3 years) cancers. However, the mean parity for cervical cancer (7.0 ± 3) was higher than those of ovarian cancer (3 ± 3), choriocarcinoma (3.5 ± 4) and endometrial cancer (4 ± 3). The mean age at menarche for women with cervical cancer (14.5 ± 0.71 years) was lower than for those with choriocarcinoma (15 ± 0 years), ovarian (15.5 ± 2.1 years) and endometrial (16 ± 0 years) cancers. -
Influence of Age on Histologic Outcome of Cervical Intraepithelial Neoplasia
www.nature.com/scientificreports OPEN Infuence of age on histologic outcome of cervical intraepithelial neoplasia during observational Received: 10 May 2017 Accepted: 6 April 2018 management: results from large Published: xx xx xxxx cohort, systematic review, meta- analysis Christine Bekos1, Richard Schwameis1, Georg Heinze2, Marina Gärner1, Christoph Grimm1, Elmar Joura1,4, Reinhard Horvat3, Stephan Polterauer1,4 & Mariella Polterauer1 Aim of this study was to investigate the histologic outcome of cervical intraepithelial neoplasia (CIN) during observational management. Consecutive women with histologically verifed CIN and observational management were included. Histologic fndings of initial and follow-up visits were collected and persistence, progression and regression rates at end of observational period were assessed. Uni- and multivariate analyses were performed. A systematic review of the literature and meta-analysis was performed. In 783 women CIN I, II, and III was diagnosed by colposcopically guided biopsy in 42.5%, 26.6% and 30.9%, respectively. Younger patients had higher rates of regression (p < 0.001) and complete remission (< 0.001) and lower rates of progression (p = 0.003). Among women aged < 25, 25 < 30, 30 < 35, 35 < 40 years, and > 40 years, regression rates were 44.7%, 33.7%, 30.9%, 27.3%, and 24.9%, respectively. Pooled analysis of published data showed similar results. Multivariable analysis showed that with each fve years of age, the odds for regression reduced by 21% (p < 0.001) independently of CIN grade (p < 0.001), and presence of HPV high-risk infection (p < 0.001). Patient’s age has a considerable infuence on the natural history of CIN – independent of CIN grade and HPV high- risk infection. -
Clinical Radiation Oncology Review
Clinical Radiation Oncology Review Daniel M. Trifiletti University of Virginia Disclaimer: The following is meant to serve as a brief review of information in preparation for board examinations in Radiation Oncology and allow for an open-access, printable, updatable resource for trainees. Recommendations are briefly summarized, vary by institution, and there may be errors. NCCN guidelines are taken from 2014 and may be out-dated. This should be taken into consideration when reading. 1 Table of Contents 1) Pediatrics 6) Gastrointestinal a) Rhabdomyosarcoma a) Esophageal Cancer b) Ewings Sarcoma b) Gastric Cancer c) Wilms Tumor c) Pancreatic Cancer d) Neuroblastoma d) Hepatocellular Carcinoma e) Retinoblastoma e) Colorectal cancer f) Medulloblastoma f) Anal Cancer g) Epndymoma h) Germ cell, Non-Germ cell tumors, Pineal tumors 7) Genitourinary i) Craniopharyngioma a) Prostate Cancer j) Brainstem Glioma i) Low Risk Prostate Cancer & Brachytherapy ii) Intermediate/High Risk Prostate Cancer 2) Central Nervous System iii) Adjuvant/Salvage & Metastatic Prostate Cancer a) Low Grade Glioma b) Bladder Cancer b) High Grade Glioma c) Renal Cell Cancer c) Primary CNS lymphoma d) Urethral Cancer d) Meningioma e) Testicular Cancer e) Pituitary Tumor f) Penile Cancer 3) Head and Neck 8) Gynecologic a) Ocular Melanoma a) Cervical Cancer b) Nasopharyngeal Cancer b) Endometrial Cancer c) Paranasal Sinus Cancer c) Uterine Sarcoma d) Oral Cavity Cancer d) Vulvar Cancer e) Oropharyngeal Cancer e) Vaginal Cancer f) Salivary Gland Cancer f) Ovarian Cancer & Fallopian -
Core Curriculum for Surgical Technology Sixth Edition
Core Curriculum for Surgical Technology Sixth Edition Core Curriculum 6.indd 1 11/17/10 11:51 PM TABLE OF CONTENTS I. Healthcare sciences A. Anatomy and physiology 7 B. Pharmacology and anesthesia 37 C. Medical terminology 49 D. Microbiology 63 E. Pathophysiology 71 II. Technological sciences A. Electricity 85 B. Information technology 86 C. Robotics 88 III. Patient care concepts A. Biopsychosocial needs of the patient 91 B. Death and dying 92 IV. Surgical technology A. Preoperative 1. Non-sterile a. Attire 97 b. Preoperative physical preparation of the patient 98 c. tneitaP noitacifitnedi 99 d. Transportation 100 e. Review of the chart 101 f. Surgical consent 102 g. refsnarT 104 h. Positioning 105 i. Urinary catheterization 106 j. Skin preparation 108 k. Equipment 110 l. Instrumentation 112 2. Sterile a. Asepsis and sterile technique 113 b. Hand hygiene and surgical scrub 115 c. Gowning and gloving 116 d. Surgical counts 117 e. Draping 118 B. Intraoperative: Sterile 1. Specimen care 119 2. Abdominal incisions 121 3. Hemostasis 122 4. Exposure 123 5. Catheters and drains 124 6. Wound closure 128 7. Surgical dressings 137 8. Wound healing 140 1 c. Light regulation d. Photoreceptors e. Macula lutea f. Fovea centralis g. Optic disc h. Brain pathways C. Ear 1. Anatomy a. External ear (1) Auricle (pinna) (2) Tragus b. Middle ear (1) Ossicles (a) Malleus (b) Incus (c) Stapes (2) Oval window (3) Round window (4) Mastoid sinus (5) Eustachian tube c. Internal ear (1) Labyrinth (2) Cochlea 2. Physiology of hearing a. Sound wave reception b. Bone conduction c. -
Once in a Lifetime Procedures Code List 2019 Effective: 11/14/2010
Policy Name: Once in a Lifetime Procedures Once in a Lifetime Procedures Code List 2019 Effective: 11/14/2010 Family Rhinectomy Code Description 30160 Rhinectomy; total Family Laryngectomy Code Description 31360 Laryngectomy; total, without radical neck dissection 31365 Laryngectomy; total, with radical neck dissection Family Pneumonectomy Code Description 32440 Removal of lung, pneumonectomy; Removal of lung, pneumonectomy; with resection of segment of trachea followed by 32442 broncho-tracheal anastomosis (sleeve pneumonectomy) 32445 Removal of lung, pneumonectomy; extrapleural Family Splenectomy Code Description 38100 Splenectomy; total (separate procedure) Splenectomy; total, en bloc for extensive disease, in conjunction with other procedure (List 38102 in addition to code for primary procedure) Family Glossectomy Code Description Glossectomy; complete or total, with or without tracheostomy, without radical neck 41140 dissection Glossectomy; complete or total, with or without tracheostomy, with unilateral radical neck 41145 dissection Family Uvulectomy Code Description 42140 Uvulectomy, excision of uvula Family Gastrectomy Code Description 43620 Gastrectomy, total; with esophagoenterostomy 43621 Gastrectomy, total; with Roux-en-Y reconstruction 43622 Gastrectomy, total; with formation of intestinal pouch, any type Family Colectomy Code Description 44150 Colectomy, total, abdominal, without proctectomy; with ileostomy or ileoproctostomy 44151 Colectomy, total, abdominal, without proctectomy; with continent ileostomy 44155 Colectomy, -
WHO Guidelines for Treatment of Cervical Intraepithelial Neoplasia 2–3 and Adenocarcinoma in Situ
WHO guidelines WHO guidelines for treatment of cervical intraepithelial neoplasia 2–3 and adenocarcinoma in situ Cryotherapy Large loop excision of the transformation zone Cold knife conization WHO guidelines WHO guidelines for treatment of cervical intraepithelial neoplasia 2–3 and adenocarcinoma in situ: cryotherapy, large loop excision of the transformation zone, and cold knife conization Catalogage à la source : Bibliothèque de l’OMS WHO guidelines for treatment of cervical intraepithelial neoplasia 2–3 and adenocarcinoma in situ: cryotherapy, large loop excision of the transformation zone, and cold knife conization. 1.Cervical Intraepithelial Neoplasia – diagnosis. 2.Cervical Intraepithelial Neoplasia – therapy. 3.Cervical Intraepithelial Neoplasia – surgery. 4.Adenocarcinoma – diagnosis. 5.Adenocarcinoma – therapy. 6.Cryotherapy – utilization. 7.Conization – methods. 8.Uterine Cervical Neoplasms – prevention and control. 9.Guideline. I.World Health Organization. ISBN 978 92 4 150677 9 (Classification NLM : WP 480) © World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. -
Vaginal Cancer, Risk Factors, and Prevention Risk Factors for Vaginal
cancer.org | 1.800.227.2345 Vaginal Cancer, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors for vaginal cancer. ● Risk Factors for Vaginal Cancer ● What Causes Vaginal Cancer? Prevention There's no way to completely prevent cancer. But there are things you can do that might help lower your risk. Learn more here. ● Can Vaginal Cancer Be Prevented? Risk Factors for Vaginal Cancer A risk factor is anything that affects your chance of getting a disease such as cancer. Different cancers have different risk factors. Some risk factors, like smoking, can be changed. Others, like a person’s age or family history, can’t be changed. But having a risk factor, or even many, does not mean that you will get the disease. And 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 some people who get the disease may not have any known risk factors. Scientists have found that certain risk factors make a woman more likely to develop vaginal cancer. But many women with vaginal cancer don’t have any clear risk factors. And even if a woman with vaginal cancer has one or more risk factors, it’s impossible to know for sure how much that risk factor contributed to causing the cancer. Age Squamous cell cancer of the vagina occurs mainly in older women. It can happen at any age, but few cases are found in women younger than 40. Almost half of cases occur in women who are 70 years old or older.